Research programme: anticancer cell differentiation/involution stimulants - Incyte
Alternative Names: MX 6162Latest Information Update: 19 Sep 2006
At a glance
- Originator Incyte Corporation
- Class
- Mechanism of Action Cell differentiation stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 19 Sep 2006 Discontinued - Preclinical for Breast cancer in USA (unspecified route)
- 22 Jul 2003 Data presented at the 94th Annual Meeting of the American Association for Cancer Research (AACR-2003) have been added to the Cancer pharmacodynamics section
- 30 Apr 2003 Incyte Genomics is now called Incyte Corporation